Investor Presentation on the Annual Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
HCG reported FY26 revenue of INR 25,454 Mn (up 15% YoY) driven by 12% volume growth and 3% ARPP improvement to INR 84,261. Adjusted EBITDA grew 19% YoY to INR 4,711 Mn with margin expanding 68 bps to 18.5%, demonstrating sustainable margin improvement. ROCE stood at 14.0%. Q4FY26 showed revenue of INR 6,523 Mn (+11%) and EBITDA margin of 19.2%. Key developments include North Bangalore facility launch with MR-LINAC technology, completion of INR 4,250 Mn rights issue, and announcement to divest non-core fertility business (Milann) to a promoter entity at enterprise value of INR 632 Mn, expected to close in Q1 FY27. Net Debt/EBITDA improved to 1.43x from 2.27x. International business grew strongly at 71% YoY.
HCG demonstrates healthy operational performance with margin expansion and significant deleveraging post rights issue. Divestment of Milann will sharpen focus on core oncology and improve capital efficiency. The improved balance sheet provides headroom for growth investments.